Stocks · News reference

Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings

Jul 27, 2026, 2:21 PMAvi Kapoor

Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZN BIYA CAPR CISS ENTX LVWR YYAI

Source: benzinga
Observed: Jul 27, 2026, 2:21 PM
Checked: Jul 27, 2026, 2:21 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Zacks Investment ResearchAug 27, 2026, 4:11 PMNa
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research
SMMT AZN MRK
BenzingaAug 27, 2026, 12:02 PMVandana Singh
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzinga
AMGN AZN
BenzingaAug 27, 2026, 11:05 AMBenzinga Newsdesk
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzinga
AMGN AZN
BenzingaAug 27, 2026, 6:24 AMBenzinga Newsdesk
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read original at benzinga
AMGN AZN
BenzingaAug 11, 2026, 12:01 PMBenzinga Newsdesk
Baiya International Completes Additional $2M Strategic Investments In Binance Coin
Further Advancing the Binance Plan Through Long-Term Capital Allocation While Expanding the Company's Digital Asset PortfolioSHENZHEN, China, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Baiya International Group Inc.
Read original at benzinga
BIYA
BenzingaAug 26, 2026, 2:16 PMAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
Read original at benzinga
ACHC AEO ALHC ANF BZ

Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings

Connected markets

Related headlines

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease

AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial

Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis

Baiya International Completes Additional $2M Strategic Investments In Binance Coin

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday